Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) CMO David Shapiro sold 10,000 shares of the company’s stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $293.93, for a total value of $2,939,300.00. Following the transaction, the chief marketing officer now directly owns 14,253 shares of the company’s stock, valued at approximately $4,189,384. The sale was disclosed in a filing with the SEC, which is available at this link.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 0.21% during mid-day trading on Friday, hitting $289.72. 322,789 shares of the company’s stock traded hands. Intercept Pharmaceuticals has a 1-year low of $45.55 and a 1-year high of $497.00. The stock’s 50-day moving average is $250.7 and its 200-day moving average is $290.. The company’s market cap is $6.147 billion. Intercept Pharmaceuticals also was the target of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 595,961 shares, a drop of 25.1% from the July 31st total of 795,445 shares. Based on an average trading volume of 1,067,623 shares, the days-to-cover ratio is currently 0.6 days. Approximately 4.2% of the shares of the stock are sold short.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Monday, August 11th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. On average, analysts predict that Intercept Pharmaceuticals will post $-13.34 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Intercept Pharmaceuticals in a research note on Friday, August 15th. They set an “underperform” rating and a $172.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Intercept Pharmaceuticals to a “hold” rating in a research note on Thursday, August 14th. Finally, analysts at Nomura upgraded shares of Intercept Pharmaceuticals to a “positive” rating in a research note on Tuesday, August 12th. They now have a $456.00 price target on the stock, up previously from $323.00. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. Intercept Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $472.91.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.